Angiotensin ii acetate - Generic Drug Details

What are the generic sources for angiotensin ii acetate and what is the scope of patent protection?

Angiotensin ii acetate is the generic ingredient in one branded drug marketed by La Jolla Pharma and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Angiotensin ii acetate has forty-six patent family members in twenty-three countries.

One supplier is listed for this compound.

Summary for angiotensin ii acetate

International Patents:	46
US Patents:	11
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	33
Clinical Trials:	6
Patent Applications:	68
Formulation / Manufacturing:	see details
DailyMed Link:	angiotensin ii acetate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for angiotensin ii acetate

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for angiotensin ii acetate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Kasr El Aini Hospital	N/A
American Lung Association	Phase 2
Johns Hopkins University	Phase 2

See all angiotensin ii acetate clinical trials

Pharmacology for angiotensin ii acetate

Drug Class	Vasoconstrictor
Physiological Effect	Vasoconstriction

Medical Subject Heading (MeSH) Categories for angiotensin ii acetate

Vasoconstrictor Agents

Anatomical Therapeutic Chemical (ATC) Classes for angiotensin ii acetate

C01CX	Other cardiac stimulants
C01C	CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
C01	CARDIAC THERAPY
C	Cardiovascular system

Paragraph IV (Patent) Challenges for ANGIOTENSIN II ACETATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GIAPREZA	Injection	angiotensin ii acetate	2.5 mg/mL	209360	1	2021-12-21

US Patents and Regulatory Information for angiotensin ii acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
La Jolla Pharma	GIAPREZA	angiotensin ii acetate	SOLUTION;INTRAVENOUS	209360-003	Dec 23, 2021		RX	Yes	Yes
La Jolla Pharma	GIAPREZA	angiotensin ii acetate	SOLUTION;INTRAVENOUS	209360-001	Dec 21, 2017		RX	Yes	Yes
La Jolla Pharma	GIAPREZA	angiotensin ii acetate	SOLUTION;INTRAVENOUS	209360-003	Dec 23, 2021		RX	Yes	Yes
La Jolla Pharma	GIAPREZA	angiotensin ii acetate	SOLUTION;INTRAVENOUS	209360-002	Dec 21, 2017		DISCN	Yes	No
La Jolla Pharma	GIAPREZA	angiotensin ii acetate	SOLUTION;INTRAVENOUS	209360-003	Dec 23, 2021		RX	Yes	Yes
La Jolla Pharma	GIAPREZA	angiotensin ii acetate	SOLUTION;INTRAVENOUS	209360-002	Dec 21, 2017		DISCN	Yes	No

International Patents for angiotensin ii acetate

Country	Patent Number	Title	Estimated Expiration
South Korea	20180108639	안지오텐신 II를 투여하는 방법
Eurasian Patent Organization	201691258	АНГИОТЕНЗИН II САМОСТОЯТЕЛЬНО ИЛИ В КОМБИНАЦИИ ДЛЯ ЛЕЧЕНИЯ ГИПОТЕНЗИИ
Eurasian Patent Organization	202092463	АНГИОТЕНЗИН II САМОСТОЯТЕЛЬНО ИЛИ В КОМБИНАЦИИ ДЛЯ ЛЕЧЕНИЯ ГИПОТЕНЗИИ
Japan	2017501154	低血圧治療のための単独または併用使用されるアンギオテンシンＩＩ
Cyprus	1122604
Serbia	59804	ANGIOTENZIN II U KOMBINACIJI ZA LEČENJE HIPOTENZIJE (ANGIOTENSIN II IN COMBINATION FOR THE TREATMENT OF HYPOTENSION)